Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
received the first dose of Shingrix in September 2023 and hasn't received a second dose yet; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 88-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose in SEP-2023). On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: received the first dose of Shingrix in September 2023 and hasn't received a second dose yet). The outcome of the incomplete course of vaccination was not applicable. Additional Information: GSK Receipt Date: 04-APR-2025 The pharmacist reported that a patient received 1st dose of Shingrix in September 2023 and had not received second dose yet. The Vaccine Administration Facility is the same as Primary Reporter Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.